Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An open, single centre, phase I study in male adolescents with asthma, aged 12 to 17 years, to assess pharmacokinetics of orally administered AZD1981 tablets 100mg twice daily for 6½ days
The primary objective of the study is to investigate the PK of orally administered AZD1981 in male adolescents with asthma.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB, European Regulatory Affairs
Update Il y a 4 ans
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS)[PLATO – A Study of PLATelet inhibition and Patient Outcomes]
The primary objective of this study is to test that AZD6410 is superior to clopidogrel for prevention of vascular events (death from vascular causes, MI, stroke) in patients with non-ST or ST elevatio...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A phaseIII study of IRESSA treatment beyond progression in addition to Chemotherapy versus Chemotherapy alone
To evaluate Progression Free Survival (PFS) in patients who have ‘‘acquired resistance’’ to first line gefitinib
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate
To determine the preliminary anti-tumour activity of AZD2171 (45 mg/day) in GIST patients by assessment with FDG-PET following 8 days and 4 weeks of dosing (central review of SUVmax).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A randomised, open -label, parallel-group, international, multicenter phase III study of oral ZD1839 (IRESSA) versus intravenous docetaxel (Taxotere) in patients with locally advanced or metastatic recurrent non small cell lung cancer who have previously received platinum based chemotherapy
To compare overall survival between ZD1839 and docetaxel
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A late stage clinical trial to investigate the efficacy and safety of AZD9291 versus Gefitinib or Erlotinib in patients with locally advanced or metastatic Non-Small Cell Lung Cancer
To assess the efficacy of single agent AZD9291 compared with standard of care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) therapy as measured by progression free surviv...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis
The primary objective of this study is to assess the efficacy of bicalutamide when used in combination with anastrozole in terms of a reduction in growth rate after 12 months treatment of precocious p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 4 ans
Étude D5330C00004 : étude de phase 1 non-randomisée visant à évaluer la sécurité d’emploi, la tolérance, la pharmacocinétique et l’efficacité de l’AZD6738 en association à une chimiothérapie cytotoxique et/ou un réparateur de DNA ou un agent anticancéreux chez des patients ayant une tumeur solide avancée.
L’AZD6738 est un inhibiteur de serine/threonine protéine kinases disponible par voie orale capable d’inhiber la proliferation cellulaire et les mécanismes de réparation de l’ADN. Dans les études précl...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
To investigate safety and efficacy of AZD9291 when given orally to patients with EGFRm+/T790M+ non small cell lung cancer. Patients will be chosen from those who have already been prescribed an EGRf TKI medicine (such as Iressa or Tarceva) Studiare la sicurezza e l'efficacia di AZD9291 somministrato per via orale in pazienti con Tumore Polmonare Non a Piccole Cellule Localmente Avanzato o Metastatico EGFRm + / T790M +. I pazienti saranno scelti fra coloro che hanno già effettuato trattamento con EGRf TKI (ad esempio come Iressa o Tarceva)
To assess the efficacy of AZD9291 by assessment of Objective Response Rate (ORR) Valutare l’efficacia di AZD9291 secondo la valutazione del Tasso di Risposta Oggettivo
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Bronchiectasis
To investigate whether AZD9668 shows evidence of efficacy in bronchiectasis patients by investigation of: · Absolute and percentage neutrophil cell count in the sputum · Signs and symptoms of bronch...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next